JP2015514771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514771A5 JP2015514771A5 JP2015507143A JP2015507143A JP2015514771A5 JP 2015514771 A5 JP2015514771 A5 JP 2015514771A5 JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015514771 A5 JP2015514771 A5 JP 2015514771A5
- Authority
- JP
- Japan
- Prior art keywords
- polyarginine peptide
- polyarginine
- composition
- cysteines
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010011110 polyarginine Proteins 0.000 claims description 32
- 235000018417 cysteine Nutrition 0.000 claims description 19
- 150000001945 cysteines Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 235000009697 arginine Nutrition 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000003889 eye drop Substances 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 150000001484 arginines Chemical class 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 2
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000003961 neuronal insult Effects 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 230000003466 anti-cipated effect Effects 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 229940098462 oral drops Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625349P | 2012-04-17 | 2012-04-17 | |
| US61/625,349 | 2012-04-17 | ||
| PCT/US2013/036938 WO2013158739A1 (en) | 2012-04-17 | 2013-04-17 | Neuroprotective composition and method of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514771A JP2015514771A (ja) | 2015-05-21 |
| JP2015514771A5 true JP2015514771A5 (enExample) | 2016-06-16 |
Family
ID=49384027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507143A Pending JP2015514771A (ja) | 2012-04-17 | 2013-04-17 | 神経保護性組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150126457A1 (enExample) |
| EP (1) | EP2872160A4 (enExample) |
| JP (1) | JP2015514771A (enExample) |
| AU (1) | AU2013249337A1 (enExample) |
| CA (1) | CA2870711A1 (enExample) |
| WO (1) | WO2013158739A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2872160A4 (en) | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
| CN106170491B (zh) * | 2013-10-30 | 2020-07-24 | 阿尔杰妮卡治疗学有限公司 | 神经保护肽 |
| US20170114093A1 (en) * | 2015-05-29 | 2017-04-27 | Andrew Peter Mallon | Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection |
| US20210101935A1 (en) | 2019-10-02 | 2021-04-08 | Brown University | Cyclic peptidomimetic for the treatment of neurological disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| US20130012447A1 (en) * | 2007-08-27 | 2013-01-10 | Eiketsu Sho | Protein kinase c-delta inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| JP5816550B2 (ja) * | 2009-06-22 | 2015-11-18 | 株式会社メディネット | 蛋白質の修飾剤 |
| EP2459208B1 (en) * | 2009-07-29 | 2016-09-28 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| EP2872160A4 (en) | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
-
2013
- 2013-04-17 EP EP13777758.7A patent/EP2872160A4/en not_active Withdrawn
- 2013-04-17 AU AU2013249337A patent/AU2013249337A1/en not_active Abandoned
- 2013-04-17 JP JP2015507143A patent/JP2015514771A/ja active Pending
- 2013-04-17 WO PCT/US2013/036938 patent/WO2013158739A1/en not_active Ceased
- 2013-04-17 US US14/391,293 patent/US20150126457A1/en not_active Abandoned
- 2013-04-17 CA CA2870711A patent/CA2870711A1/en not_active Abandoned
-
2016
- 2016-12-29 US US15/393,720 patent/US10040822B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520405A5 (enExample) | ||
| JP2016519128A5 (enExample) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| RU2015147876A (ru) | Пероральная дозированная форма соединений глюкагоноподобного пептида-1 | |
| JP2016532722A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| WO2008118017A3 (en) | Prame derived peptides and immunogenic compositions comprising these | |
| JP2013542919A5 (enExample) | ||
| CN102209553A (zh) | 肽制剂及其应用 | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| WO2016004093A3 (en) | Therapeutic compositions including galectin-3 inhibitors and uses thereof | |
| HK1204988A1 (en) | Methods and compositions for preventing or treating ophthalmic conditions | |
| JP2012501973A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2016514132A5 (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2019513752A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| RU2015110114A (ru) | Ангиотензин в лечении состояний головного мозга | |
| WO2012090225A3 (en) | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent | |
| HK1198279A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| WO2020099925A3 (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| HK1249011A1 (zh) | 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法 |